Doctor, why is my herpes so bad? The search continues

Journal of Infectious Diseases

Volumn 197, Issue 3, 2008, Pages 331-334

  Koelle, David M ^a,b,d   Bergemann, Tracy L ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UW Mail Stop 358117 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; GENE LOCUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VIRUS ISOLATION;

ANTIGENS, CD; CHROMOSOMES, HUMAN, PAIR 21; GENETIC PREDISPOSITION TO DISEASE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; MUTATION; PHENOTYPE; RECEPTORS, IGG; UTAH;

EID: 39349100672     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/525541     Document Type: Editorial

References (39)

1. Hobbs MR, Jones BB, Otterud BE, Leppert M, Kriesel JD. Identification of a herpes simplex labialis susceptibility region on human chromosome 21. J Infect Dis 2007; 197:340-6 (in this issue).
2. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341:1432-8.
3. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having asymptomatic herpes simplex virus type 2 infection. Ann Intern Med 1989; 110:882-7.
4. Oliver L, Wald A, Kim M, et al. Seroprevalence of herpes simplex virus infections in a family medicine clinic. Arch Fam Med 1995; 4:228-32.
5. Frenkel LM, Garratty EM, Shen JP, Wheeler N, Clark O, Bryson YJ. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann Intern Med 1993; 118: 414-8.
6. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-73.
7. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-50.
8. Leone P, Warren T, Hamed K, Fife K, Wald A. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons. Sex Transm Dis 2007; 34:900-7.
9. Kortekangas-Savolainen O, Vuorinen T. Trends in herpes simplex virus type 1 and 2 infections among patients diagnosed with genital herpes in a Finnish sexually transmitted disease clinic, 1994-2002. Sex Transm Dis 2007; 34:37-40.
10. Lekstrom-Himes JA, Pesnicak L, Straus SE. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol 1998; 72:2760-4.
11. Gilbert SC. Oral shedding of herpes simplex virus type 1 in immunocompetent persons. J Oral Pathol Med 2006; 35:548-53.
12. Kong A, Cox NJ. Allele-sharing models: LOD scores and accurate linkage tests. Am J Hum Genet 1997; 61:1179-88.
13. Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin - rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002; 30:97-101.
14. Garcia-Perez MA, Paz-Artal E, Correll A, et al. Mutations of CD40L ligand in two patients with hyper-IgM syndrome. Immunobiology 2003; 207:285-94.
15. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996; 103:408-13.
16. Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet 2003; 33:388-91.
17. Niehues T, Reichenbach J, Neubert J, et al. Nuclear factor κB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol 2004; 114:1456-62.
18. Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314:308-12.
19. Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317:1522-7.
20. Bochud P-Y, Magaret AS, Koelle DM, Aderem A, Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus type 2 infection. J Infect Dis 2007; 196:505-9.
21. Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997; 349:241-4.
22. Hurme M, Haanpaa M, Nurmikko T, et al. IL-10 gene polymorphism and herpesvirus infections. J Med Virol 2003; 70(Suppl 1): S48-50.
23. Tang YW, Cleavinger PJ, Li H, Mitchell PS, Smith TF, Persing DH. Analysis of candidate-host immunogenetic determinants in herpes simplex virus-associated Mollaret's meningitis. Clin Infect Dis 2000; 30:176-8.
24. Seppanen M, Lokki ML, Timonen T, et al. Complement C4 deficiency and HLA homozygosity in patients with frequent intraoral herpes simplex virus type 1 infections. Clin Infect Dis 2001; 33:1604-7.
25. Lekstrom-Himes JA, Hohman P, Warren T, et al. Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. J Infect Dis 1999; 179:1077-85.
26. Pereira RA, Scalzo A, Simmons A. Cutting edge: a NK complex-linked locus governs acute versus latent herpes simplex virus infection of neurons. J Immunol 2001; 166:5869-73.
27. Lundberg P, Welander P, Openshaw H, et al. A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice. J Virol 2003; 77:11661-73.
28. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-7.
29. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16: 96-113.
30. Koelle DM, Ghiasi H. Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr Eye Res 2005; 30:929-42.
31. Koelle DM. HSV-1 and 2: immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski E, et al., eds. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press, 2007:616-41.
32. Norberg P, Bergstrom T, Rekabdar E, Lindh M, Liljeqvist JA. Phylogenetic analysis of clinical herpes simplex virus type 1 isolates identified three genetic groups and recombinant viruses. J Virol 2004; 78:10755-64.
33. Kim JK, Kim YK, Hong J, et al. Isolation of the enhanced neurovirulent HSV-1 strains from Korean patients. Virus Genes 2003; 26: 115-8.
34. Bower JR, Mao H, Durishin C, et al. Intra-strain variants of herpes simplex virus type 1 isolated from a neonate with fatal disseminated infection differ in the ICP34.5 gene, glycoprotein processing, and neuroinvasiveness. J Virol 1999; 73:3843-53.
35. Sawtell NM. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 1998; 72:6888-92.
36. Sawtell NM, Poon DK, Tansky CS, Thompson RL. The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation. J Virol 1998; 72:5343-50.
37. + T cell activation during the development of stress-induced herpes simplex virus type-1 encephalitis. Brain Behav Immun 2007; 21: 791-806.
38. Miller RG, Bryan WW, Dietz MA, et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996; 47:1329-31.
39. Spruance SL. Cutaneous herpes simplex virus lesions induced by ultraviolet radiation: a review of model systems and prophylactic therapy with oral acyclovir. Am J Med 1988; 85 (Suppl 2a):43-5.